Specialty Pharma Resilience: Cumberland and Rigel Navigate Q4 Headwinds
Cumberland and Rigel Pharmaceuticals reported Q4 2025 results, highlighting strategic shifts toward high-margin specialty products and oncology expansions. While Cumberland focuses on hospital-channel optimization, Rigel is doubling down on its hematology-oncology portfolio to drive long-term growth.